DTIL Stock — Precision BioSciences Inc.: Cash, EV, Pipeline

What they do

We are a clinical stage gene editing company utilizing our novel proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. ARCUS differs from other technologies in the way it cuts, its smaller size, and its simpler structure.

Source: 10-K FY2025 via SEC EDGAR

Share price

$10.60

Market cap

$296.1M

Cash

$81.8M

Enterprise value

$214.3M

Balance sheet

Cash	$81.8M
Debt	$0.0M
Net cash	$81.8M
Enterprise value	$214.3M
Basic shares	27.9M shares
Fully diluted shares	39.4M shares
Fully diluted market cap	$418.1M
Cash per share	$2.93
Quarterly burn	$13.4M
Cash runway	4.3 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

27.6M

Pre-funded warrants

1.4M

Options

0.2M

RSUs

1.6M

Warrants

8.6M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

39.4M

Cap table as of 2025-12-31.

Price history

Loading DTIL daily closes…

Loading price history…

Next catalyst

PBGENE-DMD · Est. Nov 15, 2026 · quarter midpoint · guided Now

Recently reported

PBGENE-HBV Phase 1 Mixed · 2026-11-05

ELIMINATE-B · hepatitis b chronic

Primary: Phase 1 ELIMINATE-B measures of antiviral activity: pgRNA loss to undetectable, liver-biopsy cccDNA reduction and HBsAg reduction with PBGENE-HBV in chronic hepatitis B (the release names no formal primary endpoint) — 11 of 12 evaluable patients with detectable pgRNA at baseline (92%) achieved pgRNA loss to undetectable, including all six evaluable patients at the 0.4 mg/kg go-forward dose; 100% of patients with at least six months of follow-up maintained undetectable pgRNA

· 25 patients had received 59 administrations across four dose levels as of the September 28, 2026 data cutoff

· Paired liver biopsies from two patients at 0.4 mg/kg showed approximately 1-log (10-fold) and 1.5-log (35-fold) reductions in cccDNA

· All 24 evaluable patients had HBsAg reductions, with maximal reductions approaching 94% at 0.4 mg/kg

· First HBeAg-positive patient achieved undetectable pgRNA upon the second administration at 0.4 mg/kg, declining from 5,750 copies/mL at baseline

· 0.4 mg/kg selected as the go-forward dose; dosing in the global ELIMINATE-B2 Phase 2 study expected in the first quarter of 2027

Safety: No dose-limiting toxicities across 59 administrations in 25 patients and no serious adverse events at 0.4 mg/kg; most common adverse events were infusion-related reactions, with transient reversible ALT/AST elevations

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 15, 2026 Now quarter midpoint	PBGENE-DMD Phase 1/2 FUNCTION-DMD in Duchenne muscular dystrophy	Phase 1/2	Duchenne muscular dystrophy	Q4 2026
Dec 13, 2029 - Jan 24, 2030 in 38 mo	PBGENE-DMD (IV)	Phase 2	Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

PBGENE-HBV

Phase 1 · Active Modality: in vivo gene editing (ARCUS, LNP-delivered)

Target HBV cccDNA

Indications

Chronic hepatitis B (HBV) (Phase 1)

Status note Wholly owned in vivo ARCUS gene-editing program designed to eliminate covalently closed circular DNA (cccDNA), the source of HBV replication. Global first-in-human Phase 1/2a ELIMINATE-B trial enrolling at sites in Hong Kong, New Zealand, the U.S. and Moldova, expanding to the U.K.

PBGENE-DMD

Phase 1 · Active Modality: in vivo gene editing (ARCUS, AAV-delivered)

Target dystrophin gene (exon 45-55 excision)

Indications

Duchenne muscular dystrophy (DMD) (Phase 1)

Catalysts

— End of 2026

Status note Wholly owned development candidate for DMD: two complementary ARCUS nucleases in a single AAV excise exons 45-55 of the dystrophin gene, restoring near full-length dystrophin protein expression. Phase 1/2 FUNCTION-DMD trial in ambulatory boys ages 2-7 with mutations between exons 45 and 55; two sites active (Arkansas Children's, Washington University). FDA Rare Pediatric Disease designation (Jun 2025), Orphan Drug Designation (Jul 2025), Fast Track (Feb 2026); PRV-eligible.

Azer-cel

Phase 1 · Active Modality: cell therapy (allogeneic CAR-T)

Aliases azercabtagene zapreleucel

Partnerships Oncology rights licensed to Imugene Limited/Imugene US (Aug 2023; covers up to three additional research candidates). Autoimmune and non-cancer rights licensed to TG Therapeutics (Jan 2024; $10M upfront, up to $288.6M milestones; $7.5M clinical milestone achieved Mar 2026).

Indications

Diffuse large B-cell lymphoma (DLBCL) (Phase 1)
Progressive multiple sclerosis (Phase 1)

Status note Allogeneic CAR-T therapy. Imugene continues development in DLBCL with written FDA guidance aligned on the registrational pathway (dosing, population, endpoints, manufacturing). TG Therapeutics evaluating azer-cel in a Phase 1 trial in progressive multiple sclerosis.

PBGENE-3243

Preclinical · Active Modality: in vivo gene editing (mitochondria-targeted ARCUS)

Target mutant mitochondrial DNA (m.3243)

Status note Wholly owned candidate for m.3243-associated mitochondrial disease: mitochondria-targeted ARCUS nucleases designed to eliminate mutant mitochondrial DNA and shift heteroplasmy. Development paused to prioritize PBGENE-HBV and PBGENE-DMD.

ECUR-506

Stage not disclosed · Active Modality: in vivo gene editing (ARCUS gene insertion)

Target OTC gene (gene insertion)

Partnerships Developed by iECURE, Inc. under a development and license agreement (Aug 2021); Precision eligible for milestones and mid-single to low-double digit royalties; iECURE uses Precision's PCSK9-directed ARCUS nuclease.

Indications

Neonatal onset ornithine transcarbamylase (OTC) deficiency (Stage not disclosed)

Catalysts

— First half of 2026

Status note ARCUS-mediated targeted gene insertion approach for neonatal onset OTC deficiency. OTC-HOPE study ongoing in the U.K., U.S., Australia and Spain; FDA Regenerative Medicine Advanced Therapy (RMAT) designation. FDA alignment reached on primary/key secondary endpoints, comparators and study size that could support a BLA.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	PBGENE-DMD (IV)
Lead indication	Duchenne Muscular Dystrophy With Mutations Amenable to PBGEN
Lead phase	Phase 2
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07429240	Phase 2	Recruiting	Sponsor	DTIL	—	Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD	Q4 2026 Est. Nov 15, 2026 · quarter midpoint
NCT06680232	Phase 1	Recruiting	Sponsor	DTIL	—	HEPATITIS B CHRONIC	—
NCT07254208	Not disclosed	Enrolling by invitation	Sponsor	DTIL	—	Chronic HBV Infection	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Precision BioSciences, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Vivo Capital	4,675	no change	0.00%	2026-08-14
Sphera Biotech	0	-40,000	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

DTIL — Precision BioSciences Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

DTIL — Precision BioSciences Inc.